

Company Overview

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar is building a drug development pipeline through the licensing and acquisition of oncology therapeutics in late preclinical and clinical development stages, leveraging its scientific and clinical expertise to help reduce the risk and accelerate the clinical development of its drug product candidates. Monopar currently has three compounds in development: Phase 1b-stage camsirubicin for the treatment of advanced soft tissue sarcoma; Phase 1-stage MNPR-101 for radiopharmaceutical use in advanced cancers; and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program

Mar 5 2024, 7:00 AM EST

Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial

Feb 27 2024, 7:00 AM EST

Stock Overview

Symbol	MNPR
Exchange	Nasdaq
Market Cap	13.58m
Last Price	\$0.9136
52-Week	\$0.2739 - \$3.11

03/07/2024 04:00 PM EST

Management Team

Chandler D. Robinson, MD MBA MSc

Co-Founder, Chief Executive Officer and Board Member

Christopher M. Starr, PhD

Co-Founder and Executive Chairman of the Board

Kim R. Tsuchimoto

Chief Financial Officer, Secretary, Treasurer and Board Member

Monopar Therapeutics Inc.

1000 Skokie Blvd.
Suite 350
Wilmette, IL 60091

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.